Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Breast conserving surgery (BCS) is performed on patients with breast cancer to resect and
completely remove the cancer while conserving as much of the surrounding healthy tissue as
possible. Current methods do not allow surgeons to determine the completeness of surgical
resection in real-time. This often results in the need for a second surgical procedure, or in
some cases more than two surgical procedures in order to have confidence that all cancer has
been removed.
This Phase 3 study will evaluate the safety and efficacy of the fluorescent imaging agent PD
G 506 A for the real-time visualization of cancer during standard of care breast conserving
surgery. PD G 506 A is an investigational drug which is converted in the body into a
fluorescent molecule that accumulates in cancer cells. Patients receiving PD G 506 A will
undergo standard of care breast conserving surgery followed by fluorescence imaging and
removal of any potentially cancerous tissue left behind in the surgical cavity.